← Leaderboards
William Ross Wilcox
La Biomed Res Inst/ Harbor Ucla Med Ctr
$991,454
Attributed
$991,454
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $455.2K · FY2005–14$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$991,454 · 10
By mechanism
N01$455,151 · 1
M01$291,687 · 8
T32$244,616 · 1
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- William Wilcox$237,978
- John S. Adams$12,304,676
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationClinical ResearchPatient Oriented ResearchHuman SubjectHuman Therapy EvaluationEnzyme TherapyLabelBone DensityMaleFundingClinical TrialsFabry DiseaseAlendronateInstitutionGaucher'S DiseaseDrug KineticsAdolescence (12-20)Computer Retrieval Of Information On Scientific Projects DatabaseEnrollmentAlpha GalactosidaseFabry'S DiseaseDoseEnd PointGrant
Grant awards (12)
NEWBORN SCREENING POMPE PILOT STUDY$455,151
N01 · FY2014 · HD · contact PI
UCLA Intercampus Medical Genetics Training Program$244,616
T32 · FY2012 · GM · contact PI
CLINICAL TRIAL: A 12-WEEK STUDY TO EVALUATE THE SAFETY OF AT1001 IN PATIENTS WIT$4,386
M01 · FY2008 · RR · contact PI
A 12-WEEK STUDY TO EVALUATE THE SAFETY OF AT1001 IN PATIENTS WITH FABRY DISEASE$11,520
M01 · FY2007 · RR · contact PI
MULTI-CENTER, OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF FABRAZYME$34,906
M01 · FY2006 · RR · contact PI
MULTI-CENTER, OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF FABRAZYME IN PATIEN$55,480
M01 · FY2005 · RR
A MULTICENTER, OPEN LABEL EXTENSION STUDY AGALACTOSIDASE A (R-HAGAL)$40,349
M01 · FY2005 · RR
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY$10,718
M01 · FY2005 · RR
Multi-Center, Randomized, Double-Blind, Placebo Contro$87,938
M01 · FY2004 · RR
Multicenter, Open Label Extension Study ...A-galactosid$44,290
M01 · FY2004 · RR
Trial of Antiresorptive Therapy for Osteopenia in Pediatric Gaucher Patients$1,459
M01 · FY2004 · RR
Trial of Antiresporptive Therapy for Osteopenia in Pediatric Gaucher Patients$641
M01 · FY2004 · RR